Just two acquisitions in the first quarter, that of Intra-Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last year.
M&A recap: Big pharma starts the year mostly avoiding billion-dollar deals
HOT NEWS
Rethinking evidence generation for ultra-rare diseases
Scientific analyzes results of cerebrospinal fluid in patients with transverse myelitis. FDA’s RDEP in Context…
تُظهر الدراسة أن وجبة الإفطار الغنية بالجوز من الممكن أن تساعد في تعزيز قوة دماغك
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire Provides Press Release Distribution in Arabic
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…